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Cervical cancer is the most common female genital tract malignancy in Nigeria and majority of the patients present 
with advanced disease. It is a preventable cancer as there are well‑defined treatable premalignant phases. The 
objective of the study is to review the burden of cervical cancer, its screening modalities, and practice of screening and 
treatment in low resource countries with emphasis on Nigeria. This is a review involving internet and literature search. 
While developed countries have recorded significant reduction in the incidence of cervical cancer owing to organized 
screening programs, treatment of premalignant cervical lesions, and follow-up of treated cases, developing countries 
including Nigeria are yet to optimally utilize screening services due to lack of organized population‑based screening 
programs with only pockets of screening services which are at best opportunistic. This has not reduced the incidence 
of cancer because only a fraction of the target population is covered. Apart from this, loss to follow-up is rampant. The 
level of awareness of cervical cancer and its preventive strategies are low among the population and policymakers in 
Nigeria. There is no organized screening program, and the few services available are only opportunistic with little or 
no impact. Development of cervical cancer screening policy and institution of organized screening program targeted 
at covering ≥80% of population at risk is fundamental. There is also a need for widespread education of the populace 
on the burden of cervical cancer and the public health importance of the disease using the mass media, counseling at 
antenatal clinics, and the involvement of men will contribute immensely to reduction in the incidence of cervical cancer. 
Decentralization of services by incorporation of cervical screening and treatment in primary health care programs will 
ensure adequate rural-urban coverage.
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Introduction
Cervical cancer is the second most common cancer in women 
globally after breast cancer.[1] It is a major public health 
challenge globally and the most common malignancy of the 
female genital tract in Nigeria. It is a preventable cancer as it 
has a well-defined premalignant phase where treatment could 
be offered before invasive cancer develops. This approach 
has led to a significant decline in the incidence of cervical 
cancer in developed countries.
Screening helps to identify women with premalignant lesions, 
and treatment or follow-up could be offered as appropriate. 
Screening could also afford the detection of early stages 
of invasive cancer where institution of treatment promises 
favorable prognosis.[2] The ease with which the cervix can be 
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accessed or inspected visually by speculum examination and 
sample obtained for analysis makes cervical cancer screening 
highly feasible and practicable in clinic setting.
Epidemiology
An estimated 528,000 new cases of cervical cancer were 
diagnosed in 2012 with 266,000 deaths globally.[3] About 90% 
of these deaths occur in low- to middle-income countries, and 
if current trends persist, it was estimated that about 25% rise 
in the deaths may be recorded in the following 10 years.[4] 
Cervical cancer has a global distribution but varying incidence 
and prevalence with different geographical locations as a 
result of unequal availability and practice of screening for the 
premalignant disease.[3] Deaths from cervical cancer occur in 
the prime of lives when women are contributing immensely 
to the socioeconomic lives of the family and communities.
While the global average incidence of cervical cancer is 
15.2/100,000 women, the Sub-Saharan Africa has an incidence 
of 19.1.[5] Reports from regional population-based cancer 
registries in Nigeria revealed age-specific rate of 36.0, 30.3, 
and 21.0/100,000 women for Ibadan, Abuja, and Calabar 
cancer registries, respectively, and mean age at diagnosis of 
cervical cancer being 56.1, 52.3, and 50.1 years accordingly.[6,7] 
Occurrence of cervical cancer at lower ages is notable in the 
reports from these registries. This could be attributed to 
earlier age at sexual debut, lifestyle changes such as smoking 
and multiple sexual partners.
Due to gross underreporting of cancers in Nigeria, these 
reports may demonstrate the iceberg phenomenon. 
A community-based prevalence study by Thomas et al. in 
Ibadan Southwest Nigeria found a prevalence of 7.6% for 
cervical epithelial abnormalities (both premalignant and 
malignant lesions).[8]
Nigeria is the most populous African country. While about 
92,000 new cases of cervical cancer were recorded by the 
African regional office of the World Health Organization (WHO) 
and 57,000 deaths, Nigeria had about 10,000 new cases and 
8,000 mortalities in the same period.[4]
Etiopathogenesis
Persistent high-risk human papillomavirus (hrHPV) infection 
of the cervix is considered the main etiological factor in 
over 99% of cervical cancer. While HPV transmission is 
predominantly sexual, 90% of immunocompetent women 
will have a spontaneous resolution over a 2-year period.[9] 
Out of about 200 HPV genotypes known, over 40 types infect 
the genital tract out of which 15 are known to be oncogenic 
to humans.[10] The two most common hrHPV types are the 
HPV-16 found in 50%–70% of cervical cancers and HPV-18 
found in 7%–20%.[9]
Other hrHPV genotypes include HPV-31, 33, 35, 45, 52, and 
58. HPV genotypes that are less frequently found in cervical 
cancer include HPV-39, 51, 56, and 59. Furthermore, HPV-68 
was termed “probably carcinogenic to humans.” Low-risk 
HPV genotypes are associated with benign lesions of the 
cervix including viral warts. They are HPV-6, 11, 42, 43, 44, 
54, and 55.[9]
A cross-sectional study of HPV distribution in invasive cancer 
of the cervix in Sub-Saharan Africa found 90.4% of the cancers 
to be HPV positive with the most detected HPV genotypes 
being HPV-16 (50.7%), HPV-18 (19.2%), HPV-45 (10.1%), 
HPV-35 (9.7%), HPV-33 (5.0%), and HPV-52 (4.5%).[11]
The pattern of the age-specific prevalence of oncogenic 
HPV varies widely. In general, the prevalence is highest in 
the twenties and usually lower at older age. Majority of HPV 
infections acquired at this age are cleared by the immune 
system of the affected women; clearance becomes more 
difficult with age. In some countries, a second small peak 
in prevalence is seen in women 45–50 years, and in others, 
the prevalence is very low in all ages.[12,13] Strangely, in 
southern Nigeria, the prevalence of oncogenic HPV is high 
across all ages with slight peaks in women of 15–29 and 
60–69 years.[14,15]
Most of the predisposing factors for cervical cancer either 
increase the likelihood of HPV infection or encourage its 
persistence. Epidemiologic risk factors for cervical cancer 
include multiple sexual partners, early age at sexual debut, 
high risk sexual partner, immunosuppression from HIV 
infection or other causes and long-term oral contraceptive 
use.[9] These major risk factors have been shown to be 
prevalent in Nigeria.
Continuous metaplastic changes in the dynamic 
transformation zone predispose to HPV infection, and the 
persistence of the infection may ultimately lead to malignant 
transformation. The squamocolumnar junction (SCJ) of the 
cervix is also dynamic as it varies in location throughout 
the reproductive ages, extending outward at puberty, 
and by physiological changes, the columnar epithelium 
is transformed to squamous epithelium as it becomes 
exposed to the acidic environment of the vagina. This cycle 
is repeated following conditions that raise estrogen levels 
and lead to extensive growth of the columnar epithelium 
toward the ectocervix, such as pregnancy and use of oral 
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contraceptive pills. The transformation zone, region of the 
cervix between the old and new SCJ, is the site where HPV 
infection and persistence could develop into premalignant 
and malignant lesions as integration of the viral DNA into the 
basal cells of the epithelium results in immortalization and 
rapid turnover of the basal cells. At this phase, awareness 
and knowledge of cervical cancer coupled with good 
health-seeking behavior make a woman to get screened 
and benefit from appropriate treatment thus preventing the 
occurrence of invasive cancer.
Before the occurrence of invasive cervical cancer, the 
premalignant lesions histologically described as cervical 
intraepithelial neoplasia (CIN) are classified as CIN 
I, II, or III with decreasing tendency to spontaneous 
regression.  Identification of women at these stages through 
screening affords the opportunity of follow-up or treatment 
and thus reduction in the prevalence of cervical cancer if 
well implemented.[9,10]
Components of Cervical Cancer Prevention and 
Control
A complete cervical cancer prevention model includes 
three interdependent components: primary, secondary, 
and tertiary prevention. While HPV vaccination and health 
education form the basis of primary prevention, screening 
and treatment of premalignant cervical lesions constitute the 
secondary prevention modalities while tertiary prevention 
entails the management of invasive cervical cancer using 
surgery, radiotherapy, chemotherapy, or palliative care as 
appropriate.[1]
Screening modalities
CIN is the premalignant lesion of the cervix. In the words 
of Sir John Williams in 1886, “It presented no distinct 
symptoms, and was discovered accidentally.” Prevention 
strategies for cervical cancer have gone through series of 
revolutionary changes. The goal of screening and treating 
cervical premalignant lesion is to decrease the incidence of 
cervical cancer and the associated mortality by truncating 
the progress from precancerous lesion to invasive cancer.
The United States Preventive Services Task Force and the joint 
partnership of American Cancer Society, American Society for 
Colposcopy and Cervical Pathology, and American Society for 
Clinical Pathology (ACS/ASCCP/ASCP) recommended 3-yearly 
cervical cytology screening for women aged 21–29 years 
while those above 30 years should have cytology and HPV 
cotesting every 5 years or cytology alone every 3 years. 
Screening should be stopped at 65 years of age provided the 
results in the preceding 10 years were negative.[16]
Cytology-based screening requires obtaining exfoliated 
epithelial cells of the transformation zone and fixing on 
a slide (conventional Pap smear) or put in a transport 
medium (liquid-based cytology) for cytological analysis 
under a microscope. Advantages of conventional cytology 
include its proven effectiveness, wide acceptability in 
high-income countries, and well-established quality control 
measures. It is however difficult to introduce or maintain and 
requires clinical and laboratory quality assurance. It requires 
transportation from clinic back to the laboratory and multiple 
patient visits.[1] The liquid-based cytology additionally allows 
molecular testing from the sample collected but its laboratory 
requirements are more expensive than for conventional 
cytology. The sensitivity of Pap smear ranges from 20% to 52% 
and specificity from 90% to 95%.[17] Any abnormality found is 
classified using the Bethesda system (TBS), and appropriate 
follow-up or intervention is instituted.
TBS was designed to enhance communication between the 
laboratory and the clinician while providing reproducible 
data for global comparison. Since its inception in 1988, it 
has evolved to accommodate the improvement in technology 
as regards cervical cancer screening and prevention. The 
third update released in 2014 included an online version 
for educational purpose and also birthed the Bethesda 
Interobserver Reproducibility Study-2 (BIRST-2). TBS-2014 
takes into account the specimen type, adequacy of sample, 
result of test/interpretation, and any adjunctive testing.[18]
Visual screening methods include visual inspection with 
acetic acid (VIA) or with Lugol’s iodine to detect characteristic 
changes in the presence of precancerous lesions. Visual 
screening test is simple, inexpensive and requires brief 
training and minimal infrastructure. The results are available 
immediately, and treatment can be offered simultaneously. 
This has been described as the see-and-treat approach. It 
is prone to interobserver variation, there is the need for 
supervision, and the nonapplicability in postmenopausal 
women in whom the transformation zone is frequently within 
the endocervical canal are some of its setbacks.[1,9]
HPV DNA testing is incorporated into prevention programs 
in high resource settings as a primary screening test. The 
possibility of self-collection by the woman simply by inserting 
the small collecting brush deep into the vagina may make it 
more acceptable. Reflex HPV testing prevents overtreatment 
in women with abnormal Pap smear and normal colposcopic 
studies with negative hrHPV testing.[19] In the light of 
present-day understanding of the molecular mechanism 
of cervical cancer, detection of HPV E6 and E7 mRNA in 
liquid-based cervical cytology specimens has shown higher 
sensitivity and specificity for hrHPV screening.[20]
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Colposcopy is used in the evaluation of an abnormal 
cervical smear with the aid of illuminated low-power 
magnification (5–15×). Abnormalities such as vascular 
pattern, border characteristics, surface pattern, and area of 
lesion are better appreciated with a colposcope.[9,21] While 
colposcopy allows directed biopsy of abnormal area on the 
cervix, it is resource intensive, requires training and pathology 
services. Endocervical curettage of inaccessible portion of the 
cervix provides samples for histologic evaluation.[1]
Spectroscopic techniques have been shown to be reliable 
point-of-care tests in screening for cervical premalignant 
lesions. Working on the principle of fluorescence and 
reflectance spectroscopy, it has the potential of quantitatively 
assessing cellular and tissue changes.  Awolude et al.  reported 
a sensitivity of 92.3% for multimodal hyperspectroscopy 
among 100 previously screened women and significant 
reduction in the number of unwarranted colposcopy and 
cervical biopsy.[22] Spectroscopic finding of hr result was 
found to correlate with the histological diagnosis of cervical 
dysplasia in a study in Ekiti state, south-western Nigeria, 
thereby further supporting its usefulness in cervical cancer 
screening.[23]
The WHO recommends commencement of cervical cancer 
screening as a form of secondary prevention from the age 
of 25 years. The United States Center for Disease Control 
recommends screening between ages of 21 and 65 years. 
Several regional guidelines are also available with respect 
to human and material resources at the disposal of the 
region.[24] The screen-and-treat approach is recommended for 
low resource settings, screening being with modalities such 
as VIA while treatment could be offered with cryotherapy or 
loop electrosurgical excision procedure.[25]
The Nigeria Experience
In contrast with the developed countries where optimal 
practice of screening services has led to significant 
reduction in incidence and prevalence of cervical cancer, 
little improvement has been recorded in most developing 
countries.  Gaffikin et al. reported that lack of a comprehensive 
national screening program in Ghana coupled with low rate 
of patronage of cervical cancer screening services hamper 
its prevention in the country.[26] Lack of awareness and 
knowledge of cervical cancer further reduces uptake at the 
few centers where screening facilities are available.[27]
Lack of comprehensive policy for cervical cancer prevention 
and inadequate publicity of available strategies culminate in 
low practice of prevention modalities in many developing 
countries. Inaccessible screening facilities and high financial 
cost have been highlighted as impediments to utilization of 
such services.
About 40 million women are at risk of developing cervical 
cancer in Nigeria, with a national age-standardized incidence 
rate of 33.0 cases per 100,000 women per year.[28,29] The 
country lacks a well-implemented national cervical cancer 
policy, and late presentation of cervical cancer in majority of 
patients is common.[30,31] The situation is made worse by the 
fact that most health facilities lack appropriate infrastructure 
for effective management of the advanced disease.[30,31] Where 
they are available, the screening centers are inadequate in 
number to cater for the populace and such centers are mostly 
found in the urban settlements while the highly populated 
rural communities are underserved. Whereas primary health 
centers which are found in nearly every community are not 
equipped to provide these services. With the absence of 
organized screening policy, the screening offered to women 
occurs at the request of patients, suggestion of health 
personnel, or through awareness programs organized by 
individuals or nongovernmental organizations. Some of 
the screening programs are episodic, often concentrated 
around the period of cervical cancer prevention week or 
occasional infrequent free health services organized by 
politicians, philanthropists, and citizens in diaspora rather 
than being available all-round the year.[32] Screening services 
are also available at some secondary and tertiary health 
facilities either by state or institutional initiatives, and in 
these places, services are prostrate and epileptic for lack of 
human resources and basic materials.[33] The available data 
on cervical cancer screening in Nigeria are majorly hospital 
based and may not be representative of the populace.
There is low level of awareness of the burden of cervical 
cancer, its predisposing factors, prevention strategies, 
and centers where such services could be offered. Some 
studies among female university undergraduates across the 
country corroborated this.[34,35] In places where the level of 
awareness is high, uptake of screening is expected to be 
commensurate.
Despite the use of conventional Pap smear in some 
facilities in the country, no significant improvement in the 
incidence of cervical cancer has been reported. This may 
not be unconnected to the multiple patient visits required 
by this method along with its personnel requirement; 
the asymptomatic patient is thus easily lost to follow-up. 
This has led to the adoption of screen-and-treat approach 
recommended by the WHO using VIA while referring women 
that require treatment to the appropriate centers. Poor 
specificity and reproducibility may however challenge the use 
of VIA.[36,37] Importantly too, screening has not made much 
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impact because only a small fraction of the population at risk 
are screened. Local studies have shown that only very few 
women have had more than one Pap smear.[38]
In the year 2001, the National Reproductive Health Policy and 
Strategy aimed at achieving quality reproductive and sexual 
health for all Nigerians was developed as a follow-up of the 
International Conference on Population and Development 
held in Cairo in 1994. Cervical cancer control was captioned 
under “other reproductive health conditions” with a target to 
promote screening programs for early detection of cervical, 
breast, and prostatic cancer. National statistics in measuring 
the outcome of this plan is lacking. However, institutional 
data and those from regional cancer registries revealed no 
significant improvement in the trend. Furthermore, the 
strategic health development plan of the federal government 
for 2010–2015 did not specify the modalities for the control 
of cervical cancer.[39]
Factors  such as  other  competing health needs 
(Malaria, HIV/AIDS, etc.), poor political will, low budgetary 
allocation to health, and inadequate health service delivery 
system may be contributory to the poor progress made in 
cervical cancer control.
Facing the future
The statistics relating to cervical cancer in Nigeria is 
worrisome, and if significant improvements are to be 
recorded in the future, efforts must be made to scale-up 
screening services in every part of the country. This could 
best be achieved by a comprehensive national cervical 
cancer screening program that targets to cover ≥80% of the 
population at risk.
Education of the populace and health-care providers on 
cervical cancer, its risk factors, and preventive strategies is 
fundamental in the control of the disease. This will go a long 
way in increasing the uptake of screening and adherence 
to recommendations of treatment where applicable.[40] 
Integration of single visit screen and treat strategy in the 
routine services of primary health centers in Nigeria will 
ensure that underserved populations are reached. This will 
ensure decentralization of services and optimal rural-urban 
coverage.[33]
The role of men is vital in promoting the uptake of screening 
services. Awareness and advocacy measures should not 
exclude them if many gains are to be recorded. A large 
proportion of women have contact with the health facilities 
only in pregnancy. Thus, antenatal care education should 
incorporate cervical cancer awareness and screening 
promotion.[41]
Multimedia health education and mass media campaigns are 
veritable tools to improve uptake of cervical cancer screening 
services. They could be employed to create awareness and 
address pertinent issues and women’s fears concerning 
screening programs.[41,42] Remote communities lacking in 
basic infrastructures such as electricity could benefit from 
the use of handheld mobile colposcopes for screening and 
cryotherapy for treatment.
HPV vaccines are in use and offer primary prevention against 
cervical cancer. While available vaccines target mostly HPV 
16 and 18 which account for majority of cervical cancer 
cases worldwide, cross-protection against other oncogenic 
HPV subtypes is well known. In a study titled “Modeling 
Optimal Cervical Cancer Prevention Strategies in Nigeria,” 
Demarteau, Morhason-Bello, Akinwunmi, and Adewole found 
that in a low resource economy like Nigeria, an appropriate 
combination of vaccination and screening will ensure 
efficient use of limited resources.[43] Unlike most low resource 
countries where GAVI has introduced free HPV vaccine as 
part of routine immunization, Nigeria has not been listed 
for this benefit because of our inability to deliver the routine 
immunization.[44]
Conclusion
Despite the feasibility of cervical cancer eradication through 
screening and treatment of premalignant lesions, the 
statistics in the developing countries is appalling. Barriers 
to effective screening range from low level of awareness 
of the disease in the generality of the populace including 
the literate to lack of organized screening policy and poor 
rural-urban coverage. There is a need to intensify global 
prevention through advocacy, education, information, and 
carriage of preventive programs to reach every woman 
including rural community dwellers by integration of cervical 
cancer screening into primary health-care services in the 
country.
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